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Abstract  
Aims 
Beta-lactam dose optimisation in critical care is a current priority. We aimed to review the PK 
of three commonly used beta-lactams (amoxicillin+/-clavulanate, piperacillin-tazobactam and 
meropenem) to compare PK parameters reported in critically and non-critically ill neonates, 
children and adults, and to investigate whether allometric and maturation scaling principles 
could be applied to describe changes in PK parameters through life. 
Methods 
A systematic review of PK studies of the three drugs was undertaken using MEDLINE and 
EMBASE. Pharmacokinetic parameters and summary statistics were extracted and scaled 
using allometric principles to 70 kg individual for comparison. Pooled data was used to model 
clearance maturation and decline using a sigmoidal (Hill) function.  
Results 
A total of 130 papers were identified. Age ranged from 29 weeks–82 years and weight from 
0.9–200 kg. PK parameters from critically ill populations were reported with wider confidence 
intervals than those in healthy volunteers, indicating greater PK variability in critical illness. 
The standard allometric size and sigmoidal maturation model adequately described increasing 
clearance in neonates and a sigmoidal model was also used to describe decline in older age. 
Adult weight-adjusted clearance was achieved at approximately 2 years post menstrual age. 
Changes in volume of distribution were well described by the standard allometric model, 
although amoxicillin data suggested a relatively higher volume of distribution in neonates.  
Conclusions 
Critical illness is associated with greater PK variability than in healthy volunteers. The 
maturation models presented will be useful for optimising beta-lactam dosing, although a 
prospective, age-inclusive study is warranted for external validation.  
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What is already known on this subject: 
 Antimicrobial resistance and high sepsis related mortality has led to increasing interest 
in dose optimisation of antibiotics 
 Pharmacokinetic data from paediatric and neonatal critically ill populations is lacking 
 Modern modelling approaches, using size and age maturation functions may allow 
extrapolation of PK data from adults to children 
What this study adds: 
 To our knowledge, this is the first review of the pharmacokinetics of amoxicillin, 
clavulanic acid, meropenem and piperacillin-tazobactam across all ages.  
 The range of reported parameters has allowed comparison of values in critically ill and 
non-critically ill patients.  
 For the first time parameters for a clearance maturation in young patients has been 
combined with a decline function in elderly patients, generating models that could be 
used for dose optimisation in patients of all ages. 
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1 Introduction 
Infection is a common reason for admission to intensive care, accounting for 25-30% of 
admissions to adult units [1-3] and 8-12% of admissions to paediatric units [4, 5]. At any one 
time, half of the patients on an adult intensive care unit may be considered to have an infection 
[6] and up to 70% of intensive care patients will receive at least one course of antibiotics during 
their stay, regardless of age [6, 7]. Mortality for those with severe infection remains as high as 
25-30% [8, 5] and infection remains one of the most common causes of death in neonates in 
the UK and worldwide [9-11]. Infection associated healthcare costs are considerable, with 
pneumonia and septicaemia accounting for over $30 billion (approximately 8%) of US 
healthcare spending [12]. 
Provision of prompt, targeted antimicrobial therapy is a key priority in the early stages of 
treatment of infection. While recent decades have seen the evolution of sepsis care bundles that 
tailor therapy for severe infection to the individual patient, antimicrobial dosing in critically ill 
patients remains largely identical to that in the non-critically ill [13]. This is despite the fact 
that pharmacokinetics in critical illness, particularly in patients at the extremes of the age 
spectrum, may be radically different from that in health or non-critical illness [14]. 
In adults, antimicrobial pharmacokinetics in critical illness is increasingly an area of interest 
for researchers. Population approaches to pharmacokinetic data modelling have afforded the 
opportunity for the investigation of pharmacokinetics in specific patient groups such as those 
with burns. However, studies are often small (n<20) and reported pharmacokinetic parameters 
vary considerably. For example, Bourget et al. reported piperacillin clearance of 6.8 L/hr/70kg 
whereas Jeon et al. reported 17.2 L/hr/70kg in critically ill patients with burns [15, 16].  
Pharmacokinetic studies of antimicrobials in paediatric and neonatal populations are limited, 
with many dosing regimens still based on extrapolation from adults [17]. Anderson and 
Holford [18] argue that the scaling with size of the majority of biological systems can be 
described using an allometric power model with fixed exponents (for example 0.75 for 
clearance). This theory is supported by other work, for example by Calvier et al. [19], who 
showed that 0.75 as a fixed scaling exponent provided a good explanation to the clearance of 
12,620 hypothetical drugs in older children, with maturation meaning this relationship breaks 
down with decreasing age.  The age at which 0.75 scaling becomes inappropriate was drug-
specific [19]. Holford et al. [20] separately argue that clearance maturation in intra-uterine, 
neonatal and early life can be described by a sigmoidal (Emax / Hill) function. Germovsek et al. 
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[21] recently showed that combining these methods describe pharmacokinetic maturation well 
in neonates and children in a review of midazolam and gentamicin pharmacokinetics. Other 
examples of the success of this combined allometric and maturation approach include the 
busulfan model by McCune et al. [22] and a comparison of morphine models by Holford et al. 
[23]. One criticism of the focus on paediatric patients in these studies is that a common standard 
adult mature value is assumed, whereas we know drug clearance declines with age [24]. To 
recommend beta-lactam dosing for patients of all ages, it would seem sensible to develop a 
model based on data from the whole population. 
We therefore undertook a review of pharmacokinetic studies of three commonly used beta-
lactam antibiotics: amoxicillin (+/- clavulanic acid), meropenem and piperacillin-tazobactam. 
Our aim was to compare pharmacokinetic parameters reported in critically ill and non-critically 
ill neonates, children and adults, and to investigate whether allometric and maturation scaling 
principles could be applied to describe changes in pharmacokinetic parameters through life. 
2 Methods: 
2.1 Data source and search strategy 
The US national library of medicine PubMed search engine (including MEDLINE database) 
and EMBASE electronic database (using Wolters Kluwer OVID search engine) were used to 
search for human studies [25-27]. Drug name (e.g. ‘amoxicillin’) and ‘pharmacokinetic*’ were 
the key words searched for. Results were taken up to the 30th week of 2017. 
2.2 Eligibility criteria 
English-language studies were included that published pharmacokinetic parameters from 
original data or used data for which pharmacokinetic parameters had not been published 
previously, contained description of participant characteristics and the methods used for 
obtaining pharmacokinetic parameters, and included 8 or more subjects (in order to exclude 
small case series or case reports). 
2.3 Data extraction 
We extracted the following data: number of participants, patient population and clinical setting, 
methods for estimating pharmacokinetic parameters and final structural model used (where 
compartmental methods were used), summary statistics of the age and weight of the study 
group, and pharmacokinetic parameters (clearance and volume of distribution). 95% 
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confidence intervals for population mean values of pharmacokinetic parameters were recorded 
where published (including Bootstrap analyses) or were calculated, assuming a Student’s t-
distribution where standard deviation or standard error were published.  
2.4 Scaling of parameters 
Pharmacokinetic parameters were scaled to 70 kg, using mean participant weight (or median 
where mean not published). Volume of distribution was scaled linearly with weight and 
clearance was scaled with an allometric exponent of 0.75, as described previously [18] 
(equations 1). For parameters that were already allometrically scaled to 70 kg, the typical 
pharmacokinetic values were used directly from the source paper. 
Equations 1 Allometric scaling of volume (top) and clearance (bottom) 
parameters 
𝑉𝐷𝑠𝑐𝑎𝑙𝑒𝑑 = 𝑉𝐷𝑠𝑡𝑢𝑑𝑦 (
70
𝑀𝑒𝑎𝑛 𝑤𝑒𝑖𝑔ℎ𝑡
) 
𝐶𝐿𝑠𝑐𝑎𝑙𝑒𝑑 = 𝐶𝐿𝑠𝑡𝑢𝑑𝑦 (
70
𝑀𝑒𝑎𝑛 𝑤𝑒𝑖𝑔ℎ𝑡
)
0.75
 
Where 𝑉 and 𝐶𝐿 are volume of distribution and clearance values identified from 
the study scaled to a 70 kg individual using the mean weight from the study 
participants (median used where mean not presented).   
 
2.5 Data summary measures 
Population mean/median pharmacokinetic parameters with confidence intervals were plotted 
and compared in different populations using analysis of variance (ANOVA), where appropriate 
(adults/children/neonates, healthy/critically ill). Where comparisons between study groups 
were made (e.g. adult healthy and adult critically ill), unweighted mean parameter values were 
used. Unweighted means were used to avoid over-influence of one or two larger studies in 
specific populations groups e.g. Udy et al. study (n=48) of piperacillin in patients with 
augmented renal clearance [28]. Neonates were less than 28-days corrected age, children 28-
days corrected age to 18 years and adults were aged over 18. Where corrected age in 
prematurely delivered neonates is chronological age from birth minus the number of days of 
prematurity. Prematurity is defined as birth earlier than 36 weeks gestation.  
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2.6 Modelling maturation-decline of pharmacokinetics through life 
Pooled data (unweighted mean parameter estimates) were used to model the effect of ageing 
on pharmacokinetic parameters. A sigmoidal (Hill) function (Equation 2) was fitted to 
clearance values to model maturation of drug clearance with age [21]. Post-menstrual age was 
used (chronological age plus number of weeks gestation at birth) in these models. Similarly, a 
sigmoidal decline function was fitted to model decline in function in old age. An exponential 
error model was used as these parameters are commonly assumed to be log-normally 
distributed. Studies where a majority of participants were receiving some form of renal 
replacement therapy were excluded from this analysis. Parameters for these functions were 
estimated using NONMEM version 7.3 (ICON plc)[29]. Model fit was assessed using 
established statistical and graphical methods, including likelihood-based diagnostics (via the 
NONMEM objective function value) and assessment of model simulation properties (visual 
predictive check). Model plots and graphical analysis was undertaken using R language and 
environment for statistical computing, with the ggplot2 package [30, 31] 
Equation 2 Clearance maturation decline function 
𝐶𝐿 = 𝐶𝐿𝑆𝑇𝐷 . (
𝑊𝑇
70
)
0.75
. (
𝑃𝑀𝐴𝜃1
𝑃𝑀𝐴𝜃1 + 𝑃𝑀𝐴50
𝜃1
) . (1 −
𝐴𝐺𝐸𝜃2
𝐴𝐺𝐸𝜃2 + 𝐴𝐺𝐸50
𝜃2
) . exp (𝜀) 
Where:  𝐶𝐿 is model predicted clearance, 𝐶𝐿𝑆𝑇𝐷is a standardised clearance,  𝑃𝑀𝐴 
is post menstrual age in weeks and 𝑃𝑀𝐴50 is the 𝑃𝑀𝐴 age at which 50% of adult 
function is achieved; 𝐴𝐺𝐸 is age in years and 𝐴𝐺𝐸50 is the 𝐴𝐺𝐸 at which 50% of 
decline has occurred; 𝜃s are Hill coefficients. 𝐶𝐿𝑆𝑇𝐷 , 𝑃𝑀𝐴50, 𝐴𝐺𝐸50 and 𝜃s are 
estimated in the model fitting process. Model is fitted to the observed (literature) 
values with parameters chosen to minimise 𝜀. 
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3 Results 
3.1 Study selection 
A flow chart of study selection for each drug is provided in Figure 1. A total of 2082 articles 
were identified and screened, with 130 studies included in the final analysis [15, 16, 28, 32-
158]. Some studies provided pharmacokinetic parameters for two drugs (e.g. piperacillin and 
tazobactam) or several discrete groups (e.g. 0-1, 1-2 years etc.), meaning 173 sets of 
pharmacokinetic parameters were available for analysis. A summary of the articles identified, 
the patient setting, number of participants and scaled pharmacokinetic parameters with 
calculated confidence intervals is presented in supplementary material - Appendix 1. The range 
of methods used to calculate pharmacokinetic parameters included non-compartmental 
analyses and population approaches using parametric and non-parametric methodology. 
3.2 Pharmacokinetic parameters 
Table 1 summarises the demographics and pharmacokinetic parameters from the identified 
studies including the range of values identified. Plots of weight-standardised clearance (Figure 
2) and volume of distribution (Figure 3) with associated confidence intervals for population 
mean are shown. Clavulanic acid data are not presented as there were only a small number of 
studies (6) identified. There were more adult models identified (129) than paediatric (28) and 
neonatal (16). The range of ages was 25 weeks–82 years and weight 0.9–200 kg. Mean drug 
clearance and volume of distribution were similar for the 5 drugs, 8.9–13.9 L/h/70kg and 23.6–
28.9 L/70kg. Mean clearance values for adults did not appear to differ between setting 
(healthy/hospital/critical illness), although confidence intervals (Figure 2) appeared greater for 
studies in critical illness compared with healthy volunteers, perhaps suggesting greater 
pharmacokinetic variability in critically ill populations. Volume of distribution was 
significantly greater in critically ill adults compared with healthy volunteers administered 
piperacillin (25.4 vs 13.4 L/70 kg, p<0.001) and meropenem (26.2 vs 16.1, p=0.02). 
Comparison between settings for children and neonates was not possible as healthy volunteer 
data was not available.  
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3.3 Maturation-decline functions 
Parameters for the maturation-decline function for each drug are shown in Table 2. These were 
estimated using NONMEM from the pharmacokinetic parameters identified in the literature 
review. One study by Cohen-Wolkowiez et al. [132] was excluded from the piperacillin model 
fit as it used a scavenged sampling technique and the parameter estimates from this study were 
distinctly different from others in similar participants and uncertainty was large. Two 
ceftolozane-tazobactam studies [134, 135] were excluded from the tazobactam model fit as the 
clearance values from these studies deviated significantly from similar studies with 
piperacillin-tazobactam. Clavulanic acid was not modelled as the number of studies was small. 
The pooled maturation model suggests that size standardised clearance approaches adult values 
at around 2 years post-menstrual age. Figure 4 shows a visual predictive check of the pooled 
model, it appears to describe age related changes at the extremes of life well. As the amoxicillin 
data suggested higher volume of distribution in neonates, a ‘hockey stick’ function was fitted 
to these data (Figure 5), with a pivot point at 34 years (relative standard error (RSE) 29%). 
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4 Discussion 
We have, for the first time, presented a unified model to describe beta-lactam pharmacokinetics 
throughout life. This was achieved by describing the changes in beta-lactam pharmacokinetics 
in early life using the standard allometric scaling and organ maturation functions described by 
Holford et al. [20] and further extending this model by using a sigmoidal decline function to 
describe the decline in clearance associated with old age. Parameters from the pooled model 
suggest adult values of clearance are achieved at approximately two years post-menstrual age 
and at 87 years beta-lactam clearance is half of that found in young adults. This quantification 
of the effect of age on beta lactam pharmacokinetics could be used in dose-optimisation studies.   
The final parameter estimates for clearance maturation using pooled data were similar to values 
identified by Germovsek et al. [21] in their pooled analysis of gentamicin studies. These values 
are compared, along with the values suggested by Rhodin et al. [159] in their model of 
glomerular filtration maturation in Table 3, noting that these beta-lactams undergo tubular 
secretion alongside filtration. 
It is worth noting that Germovsek et al. [21], in common with other similar studies that estimate 
maturation, exclude results from older adults to avoid the confounding effects of age and the 
natural decline in renal function. In our analysis, we have successfully described this decline 
using a sigmoidal function that mirrors that used to describe maturation. We have used age as 
the covariate. It was not possible to use glomerular filtration to see if it explained all of the age 
effect, as studies were not consistent in the reporting of renal function. Some did not report it 
at all, some reported plasma creatinine and those that did report glomerular filtration used a 
variety of methods. It is likely that there will remain some age effect, even after taking filtration 
into account, as active excretion plays a part in the elimination of these drugs. A further related 
limitation is that, for similar reasons, no account was taken in our model for studies that did 
include a creatinine clearance function in their clearance models. The 𝐴𝐺𝐸50 parameter 
associated with decline in clearance with age was similar for amoxicillin and piperacillin at 79 
and 74.8 years respectively (Table 2). The value of 31.3 years for meropenem suggests the 
model may have been skewed by one higher clearance value in children from the study by Petit 
et al. [79]. The use of a decline function such as this therefore has merit as part of efforts toward 
dose optimisation for all age groups, although investigating the validity of the decline function 
presented here requires pooled data across age groups with a consistent method of measuring 
renal function. 
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When comparing clearance parameters across these populations, it is perhaps interesting to 
note that mean clearance parameters were similar between critically and non-critically ill 
individuals (Table 1). Whilst the prevalence of acute kidney injury in critical illness might lead 
one to expect lower clearance values in this population, other physiological changes including 
high cardiac output/low vascular resistance states have been recognised to increase clearance 
for some patients [160-162]. It is therefore not unexpected that mean clearance values in 
critically ill populations are similar to those in healthy populations. We think it is important to 
note that the confidence intervals for the estimates of clearance were greater in critical illness 
studies compared to healthy volunteer studies. and suggest this may indicate greater 
pharmacokinetic variability between critically ill individuals. Alternatively, this could be 
explained by greater systematic experimental error in critically ill studies. However, the 
observation arises from multiple studies (e.g. 25 critically ill and 7 healthy volunteer datasets 
for piperacillin) and confidence intervals for clearance in critically ill studies were also greater 
than hospital inpatient studies (Appendix 1 and Figure 2) where the same systematic 
experimental errors would reasonably be expected. In addition, the number of participants (n) 
was greater in critically ill studies (piperacillin mean n of 26 in critically ill versus 13 in healthy 
volunteer) which one would ordinarily anticipate leading to greater certainty in parameter 
estimates. Increased pharmacokinetic variability might be clinically significant for drugs with 
concentration-time dependent killing. For example, the 95% confidence interval for 
piperacillin clearance in the study by Shikuma et al. [89] had an almost 3-fold difference 
between lower and upper bounds (11.5–33.2 L/hr/70kg). Indeed Roberts et al., in an 
observational study of beta-lactams, reported that 16% of patients failed to achieve 
pharmacokinetic-pharmacodynamic targets and that this was associated with treatment failure 
[163]. It was also interesting to note that the clearance values identified in the literature review 
for healthy individuals are lower than those published in the summary of product characteristics 
(Table 1). For example, the mean weight-adjusted clearance for amoxicillin identified in 
healthy volunteer studies was 13.5 L/h/70kg, compared to 25L/hr published in the summary of 
product characteristics [164]. It is not immediately clear why this should be. It may be that the 
summary of product characteristic values arise from unpublished data. 
Changes in volume status are common in septic patients. Altered vascular tone and endothelial 
dysfunction lead to shifts in the distribution of fluid from the vascular to extravascular 
space [165]. This is reflected in the significantly greater volume of distribution described in the 
patient groups who are likely to be the most unwell (critically ill patients receiving piperacillin-
 This article is protected by copyright. All rights reserved. 
tazobactam and meropenem). Variability in volume of distribution was also marked in critical 
illness studies. For example, Jeon et al. [16] reported a 100-fold variation between lower and 
upper bounds of the confidence interval of the mean for volume of distribution in a study of 
burns patients (10.2–1004 L/70kg). This wide variation was all the more remarkable given this 
was a relatively large study, including 50 participants. The relatively larger volume of 
distribution of amoxicillin in neonates compared to adults reflects recognised physiological 
differences in this age group [20] and Eleveld et al. [166, 167] have recently described similar 
volume of distribution changes for remifentanil and propofol. The absence of such an effect in 
meropenem and piperacillin is probably explained by the fact that adult distributions of body 
water are reached relatively early in life and there were no studies in the very young of these 
drugs. Indeed, the pivot point of 34 years in the amoxicillin volume of distribution model is 
much later than one might expect. This probably reflects a lack of data in young children and 
adolescents to inform the pivot point in this empirical model fit.  
The greatest limitation of the maturation-decline functions described is the degree of 
uncertainty associated with the parameter estimates. The 𝑃𝑀𝐴50, for example, varied from 49 
to 398 weeks between drugs, with the large uncertainty for meropenem and tazobactam 
(relative standard error 236% and 151% respectively), probably reflecting the lack of data in 
young children. These estimates are derived from what are, in general, small pharmacokinetic 
studies, with a median of 14 participants. Furthermore, the uncertainty of pharmacokinetic 
parameter estimates from these studies was not taken into account in the estimation of the 
parameters of the maturation-decline function. By using only mean (or median) values, 
information is clearly lost and each study contributes identically to the model fit, regardless of 
size of the study or uncertainty reported. Although it is worth noting that the median number 
of participants was similar across drugs (Table 1) and weighting for sample size might have 
led to over-influence of larger studies in specific patient groups, e.g. Jeon et al. [16] n=50 burns 
patients. Similarly, requesting raw data was impractical and unlikely to yield a significant 
response in the limited time available for this study. Indeed Germovsek et al. [168] in their 
review of gentamicin obtained data from only 2 of 8 authors. Such a low response rate was felt 
unlikely to improve the inferences that can be made from this retrospective review. Particularly 
as some of the research dates back to the mid 20th century, further decreasing the potential for 
obtaining raw data. A prospective age-inclusive pharmacokinetic study could improve the 
accuracy of the parameter estimates. 
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5 Conclusions 
Over the last decade a standardised method has been developed to handle maturation of 
clearance throughout childhood. Much less work has been undertaken to describe the effect of 
ageing on clearance, limiting the potential to fit models across all age groups. Antimicrobial 
resistance and high sepsis-related mortality is a problem for patients of any age. The beta-
lactam model presented here could be used for dose optimisation throughout life, although a 
prospective study to evaluate our model is warranted. We also foresee a number of other 
potential uses for our model by others. For example, for those conducting focussed PK studies 
with narrow age ranges, the size and maturation parameters in our model could be fixed, 
thereby allowing for the exploration of other covariates after size and age are delineated. The 
parameters could potentially assist with the conduct of in vitro hollow fibre experiments 
seeking to mimic human concentration-time profiles in specific age groups. For secondary 
analysis of clinical trials where no PK are collected, our parameters could be used to predict 
typical exposure for given dose schemes. 
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Table 1 Summary statistics from literature review of pharmacokinetic studies 
Drug Amoxicillin Piperacillin Meropenem Clavulanic acid Tazobactam 
Number of studies  
 By age (neonates/children/adults) 
 By setting (healthy/hospital/ITU) 
 Haemodialysis/filtration 
23 
 7/4/13 
 9/5/10 
 1 
54 
 3/8/47 
 9/20/29 
 7 
53 
 3/8/43 
 7/15/32 
 9 
6 
 0/3/3 
 1/2/3 
 0 
31 
 3/5/23 
 4/14/13 
 4 
Median number of participants 13 14 15 13 12 
Age range (post-menstrual age) 29 weeks – 82 years 25 weeks – 71 years 27 weeks – 76 years 2.6–62 years 30 weeks – 71 years 
Weight range, kg 1.1–79.4 0.9–164.0 0.9–200.4 14.4–75.0 1.4–161.0 
Mean drug clearance (all ages), L/h/70kg (range) 
10.9 
(1.3–22.4) 
10.6 
(1.9–22.4) 
10.0 
(1.0–24.1) 
13.9 
(8.9–17.9) 
8.9 
(2.1–25.2) 
Mean clearance values (adults) by setting L/h/70kg 
(standard deviation) 
 Healthy volunteer 
 Hospital inpatient 
 Critically ill 
 
 
13.5 (4.6) 
11.3 (9.4) 
10.7 (1.7) 
 
 
11.3 (3.8) 
13.5 (4.2)  
11.3 (5.3) 
 
 
11.8 (2.4) 
10.8 (4.2) 
11.0 (4.5) 
 
 
16.1 (–) 
– 
11.0 (3.0) 
 
 
10.0 (4.9) 
12.3 (6.8) 
10.5 (4.9) 
Mean volume of distribution (all ages), L/70kg 
(range) 
28.9 (10.7–53.5) 25.0 (9.8–203.7) 23.8 (8.8–50.4) 23.9 (21.0–30.4) 23.6 (9.1–63.0) 
Mean volume of distribution (adults) by setting L70kg 
(standard deviation) 
 Healthy volunteer 
 Hospital inpatient 
 Critically ill 
 
 
22.3 (9.3) 
18.3 (3.1) 
22.2 (4.7) 
 
 
13.4 (4.8)  
20.4 (4.7) p=0.04 
25.3 (9.9) p<0.001 
 
 
16.1 (2.9)  
22.0 (10.0) 
26.2 (8.2) p=0.02 
 
 
23.1 (–) 
– 
21.1 (0.2) 
 
 
23.9 (26.1) 
21.0 (5.7) 
27.2 (9.6) 
Summary of product characteristics [30-32] 
 Clearance (L/hr) 
 Volume of distribution (L) 
 
25 
21–28 
 
10–17 
17 
 
17 
17.5 
 
Not published in SPC 
 
Note some studies included multiple age groups or clinical settings. ANOVA undertaken on clearance and volume of distribution values by setting in adults. Healthy 
volunteer used as reference. p<0.05 only shown. Comparison is not possible in other age groups as healthy volunteer studies were not found. Studies in haemodialysis 
settings were excluded from the analysis of clearance data 
 This article is protected by copyright. All rights reserved. 
Table 2 Parameter estimates for clearance maturation-decline function 
Model parameter Amoxcillin  Piperacillin  Meropenem  Pooled data 
𝐶𝐿𝑆𝑇𝐷 (L/hr/70kg) 17.0 (8) 12.7 (9) 34.6 (193) 12.9 (6) 
𝜃1 4.29 (34) 1.8 (31) 1.1 (26) 3.45 (77) 
𝑃𝑀𝐴50 (weeks) 49.0 (16) 71.6 (23) 398 (236) 49.7 (32) 
𝜃2 1.95 (41) 13.8 (361) 1.11 (65) 4.0 (44) 
𝐴𝐺𝐸50 (years) 79.0 (14) 74.8 (27) 31.3 (257) 86.8 (9) 
𝜎2 
0.08 0.11 0.11 0.13  
𝐶𝐿 = 𝐶𝐿𝑆𝑇𝐷. (
𝑊𝑇
70
)
0.75
. (
𝑃𝑀𝐴𝜃1
𝑃𝑀𝐴𝜃1 + 𝑃𝑀𝐴50
𝜃1
) . (1 −
𝐴𝐺𝐸𝜃2
𝐴𝐺𝐸𝜃2 + 𝐴𝐺𝐸50
𝜃2
) . exp (𝜀) 
Where: 𝐶𝐿 is the model predicted clearance; 𝐶𝐿𝑆𝑇𝐷 is a standardised clearance; 𝑃𝑀𝐴 is post menstrual age in 
weeks and 𝑃𝑀𝐴50 is the 𝑃𝑀𝐴 age at which 50% of adult function is achieved; 𝐴𝐺𝐸 is age in years and 𝐴𝐺𝐸50 
is the 𝐴𝐺𝐸 at which 50% of decline has occurred; 𝜃s are Hill coefficients. 𝜎2 is the estimated variance of 𝜀. Data 
presented above are mean parameter estimates (% Relative standard error (RSE)) 
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Table 3 Maturation-decline function parameters from this review compared with 
published values from similar studies 
Model 
𝜽𝟏 
𝑷𝑴𝑨𝟓𝟎 
(weeks) 
Germovsek et al. [21] 4.19 (17) 45.1 (7) 
Rhodin et al. [36] 3.40 47.7 
Pooled from this review 3.45 (77) 49.7 (32) 
(
𝑃𝑀𝐴𝜃1
𝑃𝑀𝐴𝜃1 + 𝑃𝑀𝐴50
𝜃1
) 
𝑃𝑀𝐴 is post menstrual age in weeks and 𝑃𝑀𝐴50 is the 𝑃𝑀𝐴 age at which 50% of adult function 
is achieved. 𝜃1is the Hill parameter.  PMA50 and θ1 are estimated in the model fitting process.  
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Figure 1 Flow diagram of studies identified in the review of antimicrobial 
pharmacokinetics 
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Figure 2 Weight-standardised clearance values identified from literature search plotted 
against age 
Mean clearance values (standardised to a 70-kg individual) from each study are plotted with 
an associated confidence interval (where available). The size of the points is proportional to 
the number of participants. Colours are used to denote the setting of the study. There appears 
to be greater uncertainty in parameter estimates of studies in critically ill compared with healthy 
populations. As expected, there is a lower clearance in neonates and elderly populations, 
despite standardising values allometrically 
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Figure 3 Weight-standardised volume of distribution values identified from literature 
search plotted against age 
Mean volume values (standardised to a 70-kg individual) from each study are plotted with an 
associated confidence interval (where available). The size of the points is proportional to the 
number of participants. Colours are used to denote the setting of the study. There appears to be 
greater uncertainty in parameter estimates of studies in critically ill compared with healthy 
populations. Weight-based allometric scaling appears to control for effects of age, except for 
amoxicillin where there appears to be a greater volume of distribution for neonates compared 
to adults. 
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Figure 4 Visual predictive check of maturation-decline model for clearance using pooled 
data from amoxicillin, piperacillin, meropenem and tazobactam  
 
The shaded area is the interval between the 2.5th and 97.5th centiles of clearance values 
simulated using the maturation-decline function (solid black line). Simulations from the model 
encapsulate literature clearance values (coloured dots) relatively well, although some sit below 
the lower confidence level  
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Figure 5 Visual predictive check of amoxicillin volume of distribution values using 
‘hockey-stick’ function 
Shaded area is the interval between 2.5th and 97.5th centiles of amoxicillin volume of 
distribution values simulated using hockey-stick function (dashed line) 
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 Appendix 1: Summary of pharmacokinetic parameters identified in literature 
search  
Ref Population (n) 
Age (years unless 
other specified) 
Weight (kg) Structural model 
Clearance  
(L/h/70kg) 
Volume at steady state 
(L/70kg) 
Comments/modelling approach 
Amoxicillin 
[136] Adults, critically ill (13) 
62 
IQR (58–72) 
75  
IQR (70–79) 
Two compartment 
9.5 
(95% CI: 8.2–12.0) 
25.6 
(95% CI: 20.4–42.4) 
Population approach  
[137] 
Adults, critically ill 
(haemorrhagic shock) (12) 
Med 33  
range (18–51) 
Med 75  
range (61–90) 
Two compartment 
12.0 
(6.3–22.2) range only  
18.9 
(7.7–28.7) range only  
Population approach + non-compartmental 
analysis 
[138] 
Adults, hospitalised  
(57) 
67  
sd (±16) 
78  
sd (± 20) 
One compartment 
12.3 
(95% CI: 10.9–13.6) 
21.7 
(95% CI: 20.4–23.0) 
Parameters derived from pre-specified model 
using observed concentrations 
[139] Adults, long term dialysis (8) 
39  
range (17–74) 
54.2  
range (43–66) 
Two-compartment 
linear model 
4.6 
(95% CI: 3.8–5.4) 
20.5 
(95% CI: 13.3–27.8) 
Predefined model 
[140] 
Adults, pregnant requiring 
amoxicillin (44) 
30  
sd (±6.9) 
79.4  
sd (±14.0) 
Three 
compartment 
17.9 
(95% CI: 16.1–19.7) 
16.0 
(95% CI: 13.7–18.4) 
Population approach 
[137] 
Adults, healthy volunteers 
(12) 
Med 32  
Range (20–54) 
Med 74  
range (53–89) 
Two compartment 
14.4 
(12.7–18.4) range only  
30.1 
(11.2–26.6) range only  
 
[141] Adults, healthy volunteers (9) 
28.3  
range (21–45) 
66.4  
range (46–88) 
Two compartment 
13.8 
(95% CI: 11.0–16.7) 
17.6 
(95% CI: 14.4–20.8) 
Pre-specified model 
[142] 
Adults, healthy volunteers 
(24) 
range (18–32) range (57–98) 
Two compartment 
22.4 
(95% CI: 19.5–25.3) 
42.7 
(95% CI: 36.3–49.1) 
Regression analysis with pre-specified model. 
Mean weight not available. Assumed 70 kg 
[143] Adult, elderly (12) 
73.9 
range (69–83) 
64.9  
range (52–83) 
Two compartment 
11.5 
(95% CI: 10.4–12.6) 
19.6  
(95% CI: 18.7–20.5) 
Nonlinear least squares regression analysis, pre-
specified structural model 
[144] Adult, elderly (8) 
82  
range (69–87) 
67  
range (51–82) 
Non-
compartmental 
analysis 
6.7 
(95% CI: 3.0–10.4) 
21.9 
(95% CI: 14.1– 29.8) 
Parameters calculated using trapezoid rule and 
log-linear regression 
[145] Adults, healthy volunteers (9) 
29  
range (21–38) 
75.0  
range (63–94) 
Two compartment 
11.1 
(95% CI: 9.7–12.5) 
14.7 
(95% CI: 13.2–16.2) 
Nonlinear least squares regression analysis, pre-
specified structural model 
[146] Adults, healthy volunteers (8) 
range (20–30) 74.5  
range (59–91) 
Two compartment 
18.8 
(95% CI: 17.6–20.0) 
21.8 
(95% CI: 20.0–23.6) 
Iterative least-squares process, pre-specified 
structural model 
[147] 
Adults, healthy volunteers 
(12) 
27  
sd (± 3.8) 
64.8 
sd (± 5.1) Two compartment  
10.8* 
Calculated from other 
parameters 
10.7 
(95% CI: 10.4–11.0) 
Pre-specified model 
[148] Children, critically ill (50) 
2.6 
range (1/12–15) 
14.4  
range (4–65) 
Three 
compartment 
18.0 
(95% CI: 15.3–21.3) 
25.7 
(95% CI: 17.0–38.9) 
Population approach 
[149] Children, ‘seriously ill’ (15) 
6.9  
range (2–14) 
Not recorded Non-
compartmental  
16.7 
(95% CI: 15.3–18.1) 
32.8 
(95% CI: 29.8–35.8) 
Trapezoidal rule  
[150] 
Children, treated for viral 
infection or neurological 
disease (12) 
10  
range (2–14.5) 
Not reported 
Two-compartment 
21.6 
(95% CI: 19.6–23.6) 
53.5 
(95% CI: 44.5–62.5) 
Regression/trapezoidal rule 
[151] 
Infants and Children treated 
for infection (14) 
14.6 months  
(mean only) 
Not reported 
 
14.5 
(mean only reported) 
24.3 
(mean only reported) 
Regression analysis using least mean squares  
[152] Neonates, hypothermia (125) 
GA 40 weeks range 
(36–42) 
Median 
3.3 (2.1–5.1) 
Two compartment 
2.9 
(95% CI: 2.7–3.2) 
50.3 
(95% CI: 40.6–60.5) 
Population approach; allometric scaling 
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PNA 5 days (2–5) 
[153] Neonates, premature (40) 
GA 28.9 weeks 
range (24–32) 
PNA 1.1 days (1–3) 
1.1 (0.6–1.5) 
One compartment 
2.0 
(CV 6.6%) 
43.1  
(CV 7.6%) 
Population approach 
[154] Neonates, premature (17) 
GA 29 weeks  
sd (± 6/7) 
PNA 3 days 
1.2 (±0.3) 
One compartment 
1.3 
(95% CI: 1.0–1.5) 
33.8 
(95% CI: 27.8–39.8) 
Visual inspection used to determine structural 
model 
[155] Neonates, premature (150) 
GA 34.6 weeks 
range (24.9–42.4) 
PNA 0.8 days 
range (0–9) 
2.3(±1.1) 
One compartment  
2.9 
(95% CI: 2.7–3.0) 
45.5 
(95% CI: 44.0–47.0) 
Iterative two stage Bayesian fitting procedure, 
pre-specified model 
[156] Neonates, premature (11) 
PNA 26 days 
range (1–63) 
3.4 
range (2.9–3.8) 
One compartment  
2.8 
(95% CI: 2.7–2.9) 
28.7 
(95% CI: 26.8–30.6) 
Pre-specified model 
[157] Neonates, PNA > 9 days (32) 
PNA 24.7 days 
range (10–52) 
2.3 range (0.8–
4.3) 
One compartment 
5.4 
(95% CI: 4.3–6.4) 
46.2 
(95% CI: 39.4–53.0) 
Iterative two stage Bayesian fitting procedure, 
pre-specified model 
[158] Neonates (11) 
GA 38 weeks 
sd (±3) 
3 (±0.8) Non-
compartmental  
8.6 
(95% CI: 5.9–11.3) 
– 
Continuous infusion study, steady state assumed 
 
Clavulanic acid 
[136] Adults, critically ill (13) 
62   
IQR (58–72) 
75 
IQR (70–79) 
Two compartment 
8.9 
(95% CI: 6.0–12.2) 
21.8 
(95% CI: 14.2–68.1) 
Population approach  
[137] 
Adults, critically ill 
(haemorrhagic shock) (12) 
33 
range (18–51) 
Med 75 range 
(61–90) 
Two compartment 
13.1 
range (6.6–22.8)  
21 
range (13.5–32.3)  
Population approach + non-compartmental 
analysis 
[137] Adults, well volunteers (12) 
32 
range (20–54) 
74 
range (53–89) 
Two compartment 
16.1 
range (9.0–33.6)  
23.1 
range (17.8–99.2)  
Population approach + non-compartmental 
analysis 
[148] Children, critically ill (50) 
2.6 
range (1/12–15) 
14.4 
range (4–65) 
Two compartment 
12.2 
(95% CI: 10.5–14.6) 
21.6 
(95% CI: 14.2–68.1) 
Population approach 
[149] Children, ‘seriously ill’ (15) 
6.9 
range (2–14) 
Not recorded Non-
compartmental  
17.9 
(95% CI: 13.3–22.5) 
30.4 
(95% CI: 23.5–37.3) 
Trapezoidal rule  
[150] 
Children, with viral infection 
& neurological disease (12) 
10 
range (2–14.5) 
Not reported 
Two-compartment 
15.2 
(95% CI: 13.4–17.0) 
25.8 
(95% CI: 23.6–28.0) 
Regression/trapezoidal rule 
Mean or median values presented. With associated range, interquartile range (IQR) or standard deviation (sd). 95% confidence intervals have been calculated, where standard deviation or standard error data was 
available, assuming a student’s t-distribution. GA is gestational age, PMA is post-menstrual age 
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Ref Population (n) 
Age (years unless 
other specified) 
Weight (kg) 
Structural 
model 
Clearance  
(L/h/70kg) 
Volume at steady state 
(L/70kg)* 
Comments/modelling approach 
Piperacillin 
[85] Adults, critically ill (15) 
62 
IQR (58–72) 
78  
IQR (70–79) 
Two 
compartment 
12.2 
IQR (9.4–20.9) 
23.1 
IQR (15.7–22.6) 
Population approach  
[86] 
Adults, critically ill, septic 
shock (high creatinine) (15) 
66  
IQR (59, 79) 
80  
IQR (70.2,95) 
Two 
compartment 
3.3 
(95% CI: 2.1–4.4) 
9.8 
(95% CI: 7.4 –12.2) 
Non-linear mixed-effects methods 
[87] Adults, critically ill (18) 
56  
range (31.4–80.8) 
80.0  
range (47–140) 
Two 
compartment 
(+ lung 
compartment)  
10.9 
(95% CI: 7.9 –14.0) 
*10.2 
(95% CI: 8.1 –12.4) 
Non-parametric population approach.  
*central compartment only available 
[88] Adults, critically ill (22) 
65 
range (22–89) 
70 
range (38–120) 
One 
compartment 
10.0 
(95% CI: 7.0 –13.0) 
32.1 
(95% CI: 25.7–38.5) 
Non-linear mixed-effects methods 
[89] 
Adults, critically ill surgical  
(11) 
43.6  
sd (±15.9) 
76  
sd (±11.0) 
Two 
compartment 
22.4 
(95% CI: 11.5–33.2) 
23.0 
(95% CI: 12.4–33.7) 
Non-linear least-squares regression analysis 
[90] 
Adults, critically ill with 
sepsis (16) 
30.5 
 range (22–65) 
76.5  
range (64–86) 
Two 
compartment 
16.0 
(95% CI: 13.5–19.3) 
22.9 
(95% CI: 17.6–31.5) 
Non-linear mixed-effects methods 
[91] 
Adults, critically ill, 
indigenous Australian (9) 
43  
sd (±11) 
76  
sd (±11) 
Two 
compartment 
5.3 
(95% CI: 3.0–7.6) 
*13.4 
(95% CI: 8.7–18.0) 
P-metrics compartmental analysis—
parametric/non-parametric not specified. *central 
compartment only published 
[28] 
Adults, critically ill with 
augmented renal clearance 
(48) 
47.3  
sd (±17.9) 
88.4  
sd (±24.2) 
Two 
compartment 
13.7 
(95% CI: 11.8–15.9) 
30.6 
(95% CI: 9.3–47.6) 
Non-linear mixed-effects methods 
[15] 
Adults, critically ill with burns 
and infection (10) 
37.7  
range (22–50) 
77.8  
range (45–105) 
Non-
compartmental  
6.8 
(95% CI: 4.3–9.3) 
14.2 
(95% CI: 10.8–17.7) 
Unspecified 
[16] 
Adults, critically ill with burns 
and infection (50) 
50.1  
range (20–83) 
66.9  
range (50–90) 
Two 
compartment 
17.2 
(95% CI: 13.9–19.0) 
43.3 
(95% CI: 10.2–1004.5) 
Non-linear mixed-effects methods 
[92] 
Adults, critically ill with burns 
and infection (9) 
38  
range (20–58) 
80  
range (55–96) 
Two 
compartment 
13.5 
(95% CI: 9.1–17.9) 
48.1 
(95% CI: 18.4–77.9) 
Nonlinear least-squares regression 
[93] 
Adults, critically ill, obese and 
non-obese (50) 
50  
sd (±15) 
104  
sd (±35) 
Two 
compartment  
10.4  
(95% CI: 8.9–11.9) 
33.0* 
(95% CI: 29.3–36.6) 
Not specified. Presume population approach 
based on analysis of residuals. *central 
compartment only published 
[94] Adults, critically ill, obese (9) 
57  
sd (+11) 
164  
sd (±50) 
One 
compartment 
3.2 
(95% CI: 2.5–3.8) 
13.2 
(95% CI: 10.7–15.7) 
trapezoidal rule and log-linear least squares 
[95] 
Adults, critically ill, hospital 
acquired pneumonia (50) 
68.4  
sd (± 7.1) 
66.7  
sd (± 8.6) 
Non-
compartmental  
11.7 
(95% CI: 11.0–12.4) 
Volume not published Log trapezoidal method 
[96] 
Adults, critically ill requiring 
haemofiltration (16) 
57  
sd (± 16) 
74  
sd (±8) 
Two 
compartment 
7.6 
(95% CI: 4.7–11.0) 
40.0 
(95% CI: 26.7–57.3) 
Population approach 
[97] 
Adults, critically ill requiring 
haemofiltration (20) 
63  
IQR (54–74.8) 
81.7  
IQR (64.6, 93.2) 
Non-
compartmental  
3.9 
IQR (2.9–5.5) 
Volume not published Unspecified 
[98] 
Adults, critically ill, requiring 
haemofiltration (42) 
56.8  
sd (± 15.5) 
95.1  
sd (±26.8) 
One 
compartment 
3.1 
IQR (0.2–6.0) 
25.4 
IQR (2.9–47.8) 
‘standard first-order equations’ 
[99] 
Adults, critically ill, requiring 
haemofiltration (10) 
62  
IQR (54.5–68.8) 
87.5  
IQR (68.5–98.8) 
Two 
compartment 
5.8 
(95% CI: 5.2–6.7) 
16.2 
(95% CI: 13.0–20.2) 
Non-linear mixed-effects methods 
[100] 
Adults, critically ill, requiring 
haemofiltration (19) 
70  
range (39–82) 
80  
range (45–129) 
Two 
compartment 
5.5 
(95% CI: 4.5–6.7) 
28.3 
(95% CI: –6.8*–72.3) 
Non-linear mixed-effects methods. *-ve bootstrap 
estimate 
[101] 
Adults, critically ill, requiring 
haemofiltration (9) 
56.4  
sd (±15.2) 
86.6  
sd (±22.6) 
Two 
compartment 
2.1 
(95% CI: 1.2–3.0) 
20.9 
(95% CI: 12.9–29.0) 
Weighted non-linear least-square regression 
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[102] 
Adults, critically ill, requiring 
haemofiltration (10) 
51.6  
sd (±15.6) 
83.4  
sd (±21.8) 
Non-
compartmental 
4.3 
IQR (3.7–5.4) 
29.4 
IQR (20.3–34.3) 
Log-transformed concentration-time plots 
[103] 
Adults, critically ill and 
hospitalised (13) 
53.2  
sd (±13.2) 
79.6  
sd (±13.8) 
Non-
compartmental 
7.8 
(95% CI: 6.2–9.5) 
19.4 
(95% CI: 27.3–21.6) 
Linear regression of log-concentration plots and 
trapezoidal rule 
[104] 
Adults, hospitalised, 
nosocomial infections (50) 
57  
sd (± 16) 
61.1  
sd (± 10.1) 
One 
compartment  
15.2 
(95% CI: 14.1–16.3) 
24.9 
(95% CI: 21.9–27.8) 
Non-linear mixed-effects methods 
[105] 
Adults, obese, hospitalised, 
treated for infection (14) 
49  
sd (±10) 
161  
sd (± 29) 
Unspecified 
7.3 
(95% CI: 5.7–8.9) 
14.5 
(95% CI: 11.0–18.0) 
Non-linear least squares regression 
[106] 
Adults, hospitalised and 
critically ill, treated for 
infection (11) 
44.7  
sd (± 12.5) 
78  
sd (± 22.1) 
Two 
compartment  
16.1  
(95% CI: 12.3–19.9) 
17.0* 
(95% CI: 11.4–22.5) 
Non-parametric population approach. *central 
volume of distribution only published 
[107] 
Adults, hospitalised, treated 
for infection (33) 
68.8  
sd (±11) 
58.2  
sd (±10) 
Two 
compartment  
7.9 
(95% CI: 2.1–15.1) 
28.0 
(95% CI: 22.7–40.1) 
Non-linear mixed-effects methods 
[108] 
Adults, treated for intra-
abdominal infection (56) 
48  
range (18–85) 
81.8  
range (55–136) 
One 
compartment 
13.0 
(95% CI: 9.3–16.7) 
19.1 
(95% CI: 16.4–21.8) 
Non-linear mixed-effects methods 
[109] 
Adults, treated for intra-
abdominal infection (18) 
31.1  
sd (±8.5) 
75.6  
sd (±16.9) 
Non-
compartmental  
13.9 
(95% CI: 12.1–15.8) 
19.4 
(95% CI: 17.5–21.4) 
Unspecified, LAGRAN computer program 
[110] 
Adults, haematological 
malignancy, receiving 
chemotherapy (16) 
31.9  
sd (± 15.4) 
56.4  
sd (± 11.2) 
Non-
compartmental 
11.7 
(95% CI: 7.6–15.7) 
23.8 
(95% CI: 17.1–30.5) 
Calculated from time concentration plots 
[111] 
Adults, haematological 
malignancy, febrile 
neutropenic (12) 
64.5  
IQR (60.5–71.0) 
75.0  
IQR (63.7–93.2) 
Non-
compartmental 
19.2 
(95% CI: 14.7– 23.7) 
27.7 
(95% CI: 23.0–32.5) 
PKSolver 
[112] 
Adults, cystic fibrosis with 
infection (9) 
33  
sd (± 12.6) 
53.6  
sd (± 6.5) 
Two 
compartment 
20.2 
(95% CI: 17.1–23.3) 
17.3* 
(95% CI: 9.4–25.2) 
Population approach, two compartment pre 
specified. *Central volume of distribution only 
published.  
[113] 
Adults, volunteers with cystic 
fibrosis (8) 
21  
sd (± 4) 
43.1  
sd (± 7.8) 
Two 
compartment 
16.3 
(95% CI: 15.1–17.7) 
15.6  
(95% CI: 14.0–17.2) 
Population approach 
[114] 
Adults, cystic fibrosis with 
infection (13) 
*450mg/kg/day  
21.3  
sd (±6.3) 
41.8  
sd (±13) 
Non-
compartmental 
18.3 
(95% CI: 12.6–24.0) 
21.7 
(95% CI: 15.4–28.0) 
Least squares regression analysis of log-linear 
plots and trapezoidal rule 
[115] 
Adults, undergoing elective 
surgery (18) 
66.8  
sd (±12) 
72.3  
sd (±11.4) 
Non-
compartmental  
11.3 
(95% CI: 10.1–12.6) 
17.5 
(95% CI: 16.1–18.9) 
Linear regression of log-concentration plots and 
trapezoidal rule 
[116] 
Adults, undergoing prostate 
surgery (24) 
70.8  
sd (±6.6) 
61.9  
sd (±9.7) 
Three 
compartment 
10.0 
(95% CI: 2.5–17.5) 
17.3 
(95% CI: 4.3–30.3) 
Non-linear mixed-effects methods 
[117] 
Adults, hydrocephalus, treated 
for infection (9) 
58.6  
sd (±9.6) 
81.2  
sd (±10.3) 
Non-
compartmental 
10.9 
(95% CI: 9.1–12.7) 
15.8 
(95% CI: 14.1–17.4) 
Linear regression of log-concentration and 
trapezoidal rule 
[118] 
Adults, healthy volunteers 
(11) 
29  
sd (±8.9) 
69.8  
sd (±15.7) 
Non-
compartmental  
10.9 
(95% CI: 9.2–12.6) 
12.7 
(95% CI: 11.3–14.2) 
Least squares regression analysis of log-linear 
plots and trapezoidal rule 
[119] 
Adults, healthy volunteers 
(12) 
25  
range (23–30) 
78.4  
range (60.4–96.3) 
Non-
compartmental 
10.9 
(95% CI: 10.2–11.6) 
10.6 
(95% CI: 9.8–11.5) 
Non-linear iterative least-squares method 
[120] 
Adults, healthy volunteers 
(10) 
range (25–64) 70.9  
sd (±13.9) 
Non-
compartmental 
20.5 
No uncertainty reported 
30.7 
No uncertainty reported 
Data fitted to regression lines 
[113] 
Adults, healthy volunteers 
(26) 
25  
sd (± 4) 
71.1  
sd (± 11.8) 
Two 
compartment 
11.2 
(95% CI: 10.7–11.6) 
10.4  
(95% CI: 9.7–10.8) 
Population approach 
[121] 
Adults, healthy volunteers 
(12) 
25.7  
sd (± 2.4) 
68.4  
sd (± 11.7) 
Two 
compartment 
10.0 
(95% CI: 8.7–11.2) 
21.8 
(95% CI: 14.1–29.5) 
Non-linear least squares method 
[122] 
Adults, healthy volunteers 
(12) 
28  
sd (±8) 
70  
sd (±17) 
Non-
compartmental  
10.2 
(95% CI: 8.9–11.5) 
10.5 
(95% CI: 9.6–11.4) 
Least squares regression analysis of log-linear 
plots and trapezoidal rule 
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[123] Adults, healthy volunteer (10) 
25.7  
sd (±3.1) 
69.6  
sd (±9.7) 
Three 
compartment  
11.0 
Intervals not disclosed 
10.9 
Intervals not disclosed 
Non-linear mixed-effects methods 
[124] 
Adults, healthy volunteers 
(10) 
30.4 
 range (23–44) 
68.1  
sd (±12.1) 
Two 
compartment  
11.2 
(95% CI: 9.0–13.4) 
12.7 
(95% CI: 11.0–14.3) 
Nonlinear regression analysis 
[125] 
Adults, healthy volunteers, 
high dose piperacillin (10) 
30.7  
sd (±7.6) 
73.7  
sd (±15.5) 
Non-
compartmental  
6.1 
(95% CI: 4.7–7.6) 
9.9 
(95% CI: 7.7 –12.1) 
Least squares regression analysis of log-linear 
plots and trapezoidal rule 
[126] Children, critically ill (13) 
2  
range (0.75–6) 
14.5  
sd (± 6) 
Two 
compartment 
14.1 
(95% CI: 10.4–17.8) 
17.4* 
(95% CI: 8.5–26.4) 
Non-parametric. *central compartment only 
published 
[127] Children, critically ill (47) 
2.8 
 range (0.17–15) 
14  
range (3.4–45) 
Two 
compartment 
13.4 
(95% CI: 11.7–18.4) 
17.0 
(95% CI: 14.9–19.6) 
Non-linear least squares method 
[128] Children, critically ill (12) 
5  
IQR (1.75–6.5) 
17.8  
IQR (11.4,20) 
One 
compartment  
9.8 
(95% CI: 8.5–11.1) 
25.9 
(95% CI: 19.8–31.9) 
Non-linear least squares method 
[129] 
Children, oncology patients 
febrile neutropenia (21) 
7.4  
sd (± 2.1) 
28.5  
sd (± 9.7) 
Two 
compartment 
11.4 
(95% CI: 9.5–13.3) 
13.9* 
(95% CI: 10.5–17.3) 
Non-parametric. *Central volume only published 
[130] 
Children with suspected 
infection (11) 
Range (6–12) Not reported Non-
compartmental  
8.6 
(95% CI: 7.9–9.2) 
19.6 
(95% CI: 14.9–24.3) 
Least squares regression analysis of log-linear 
plots and trapezoidal rule 
[130] 
Children with suspected 
infection (12) 
Range (2–5) Not reported Non-
compartmental  
8.0 
(95% CI: 6.6–9.4) 
19.6 
(95% CI: 15.2–24.0) 
Least squares regression analysis of log-linear 
plots and trapezoidal rule 
[130] 
Children with suspected 
infection (12) 
Range (0.5–2) Not reported Non-
compartmental  
6.8 
(95% CI: 5.1–8.5) 
21 
(95% CI: 16.6–25.4) 
Least squares regression analysis of log-linear 
plots and trapezoidal rule 
[130] 
Children with suspected 
infection (12) 
Range (0.2–0.4) Not reported Non-
compartmental  
4.8 
(95% CI: 4.1–5.5) 
23.1 
(95% CI: 18.7–27.5) 
Least squares regression analysis of log-linear 
plots and trapezoidal rule 
[114] 
Children, cystic fibrosis with 
infection (15) 
9.4  
sd (±1.8) 
23.4  
sd (±7.2) 
Non-
compartmental 
16.0 
(95% CI: 13.3–18.7) 
22.4 
(95% CI: 18.5–26.3) 
Least squares regression analysis of log-linear 
plots and trapezoidal rule. 900mg/kg/day dose 
[114] 
Children, cystic fibrosis with 
infection (15) 
8.3  
sd (±3.3) 
20.8  
sd (±6.3) 
Non-
compartmental 
16.6 
(95% CI: 13.5–19.7) 
23.1 
(95% CI: 19.2–27.0) 
Least squares regression analysis of log-linear 
plots and trapezoidal rule. 600mg/kg/day dose 
[131] 
Infants and neonates treated 
for infection (71) 
PMA 37.5 weeks  
sd (±5) 
2.76  
sd (±1) 
Two 
compartment 
4.2 
(95% CI: 3.9–4.5) 
18.8* 
(95% CI: 14.8–21.8) 
Non-linear mixed-effects. *Central compartment 
only published  
[132] 
Infants and neonates, treated 
for infection (77) 
PMA 29 weeks 
range (23–40) 
0.9  
range (0.4–2.5) 
One 
compartment  
11.6 
(95% CI: 8.5–14.7) 
203.7 
(95% CI: 114.8–393.1) 
Non-linear mixed-effects. Scavenged samples 
[133] 
Infantes and neonates treated 
for infection (32) 
PMA 32 weeks 
range (25–48) 
1.4  
range (0.4–4.0) 
One 
compartment  
1.9 
(95% CI: 1.6–2.3) 
29.4 
(95% CI: 25.2–35.7) 
Non-linear mixed-effects. Dried blood spot 
samples 
Tazobactam 
[87] Adults, critically ill (18) 
56  
range (31.4–80.8) 
80.0  
range (47–140) 
Two 
compartment 
(+lung 
compartment)  
8.8 
(95% CI: 6.3 –11.3) 
*13.0 
(95% CI: 9.8–16.1) 
Non-parametric population approach.  
*central compartment only available 
[96] 
Adults, critically ill requiring 
haemofiltration 
57  
sd (± 16) 
74  
sd (±8) 
Two 
compartment 
6.7 
(95% CI: 4.6–8.6) 
39.4 
(95% CI: 17.7–53.6) 
Population approach 
[98] 
Adults, critically ill, requiring 
haemofiltration (42) 
56.8  
sd (± 15.5) 
95.1  
sd (±26.8) 
One 
compartment 
2.3 
IQR (0.08–4.5) 
28.0 
IQR (7.7–48.4) 
‘standard first-order equations’ 
[99] 
Adults, critically ill, requiring 
haemofiltration (10) 
62 
 IQR (54.5, 68.8) 
87.5  
IQR (68.5, 98.8) 
Two 
compartment 
4.3 
(95% CI: 3.5–5.3) 
14.0 
(95% CI: 10.8–18.2) 
Non-linear mixed-effects methods 
 [101] 
Adults, critically ill, requiring 
haemofiltration (9) 
56.4  
sd (±15.2) 
86.6  
sd (±22.6) 
Two 
compartment 
3.8 
(95% CI: 2.3–5.3) 
37.7 
(95% CI: 27.1–48.2) 
Weighted non-linear least-square regression 
[102] 
Adults, critically ill, requiring 
haemofiltration (10) 
51.6  
sd (±15.6) 
83.4  
sd (±21.8) 
Non-
compartmental 
3.3 
IQR (2.9–3.7) 
22.4 
IQR (16.8–25.2) 
Log-transformed concentration-time plots 
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[15] 
Adults, critically ill with burns 
and infection (10) 
37.7 
range (22-50) 
77.8  
range (45-105) 
Non-
compartmental  
17.2 
(95% CI: 11.7–22.6) 
31.1 
(95% CI: 23.6–38.7) 
Unspecified 
[103] 
Adults, critically ill and 
hospitalised (13) 
53.2  
sd (±13.2) 
79.6  
sd (±13.8) 
Non-
compartmental 
5.9 
(95% CI: 4.6–7.2) 
17.9 
(95% CI: 13.0–22.7) 
Linear regression of log-concentration plots and 
trapezoidal rule 
[104] 
Adults, hospitalised, 
nosocomial infections (50) 
57  
sd (± 16) 
61.1  
sd (± 10.1) 
One 
compartment  
6.4 
(95% CI: 4.3–7.6) 
18.3 
(95% CI: 15.2–19.8) 
Non-linear mixed-effects methods 
[105] 
Adults, obese, hospitalised, 
treated for infection (10) 
49  
sd (±10) 
161  
sd (± 29) Unspecified 
5.9 
(95% CI: 4.3–7.6) 
16.3 
(95% CI: 11.5–21.1) 
Non-linear least squares regression. Note low 
parameter estimates after scaling in this obese 
cohort. 
[106] 
Adults, hospitalised and 
critically ill, treated for 
infection (11) 
44.7  
sd (± 12.5) 
78  
sd (± 22.1) 
Two 
compartment  
14.0  
(95% CI: 11.1–16.8) 
19.0* 
(95% CI: 12.5–25.4) 
Non-parametric population approach. *central 
volume of distribution only published 
[107] 
Adults, hospitalised, treated 
for infection (33) 
68.8  
sd (±11) 
58.2  
sd (±10) 
Two 
compartment  
7.5  
(95% CI: 3.3–13.1) 
32.4 
(95% CI: 29.3–42.2) 
Non-linear mixed-effects methods 
[108] 
Adults, treated for intra-
abdominal infection (56) 
48  
range (18-85) 
81.8  
range (55-136) 
One 
compartment 
9.2 
(95% CI: 5.9–12.5) 
19.7 
(95% CI: 16.4–23.0) 
Non-linear mixed-effects methods 
[109] 
Adults, treated for intra-
abdominal infection (18) 
31.1  
sd (±8.5) 
75.6  
sd (±16.9) 
Non-
compartmental  
14.0 
(95% CI: 11.9–16.0) 
20.8 
(95% CI: 17.0–24.6) 
Unspecified, LAGRAN computer program 
[115] 
Adults, undergoing elective 
surgery (18) 
66.8  
sd (±12) 
72.3  
sd (±11.4) 
Non-
compartmental  
11.0 
(95% CI: 9.5–12.5) 
20.8 
(95% CI: 18.2–21.0) 
Linear regression of log-concentration plots and 
trapezoidal rule 
[116] 
Adults, undergoing prostate 
surgery (24) 
70.8  
sd (±6.6) 
61.9  
sd (±9.7) 
Three 
compartment 
9.7 
(95% CI: 2.4–16.9) 
14.8 
(95% CI: 3.7–25.9) 
Non-linear mixed-effects methods 
[117] 
Adults, hydrocephalus, treated 
for infection (9) 
58.6  
sd (±9.6) 
81.2  
sd (±10.3) 
Non-
compartmental 
10.7 
(95% CI: 8.0–13.5) 
29.1 
(95% CI: 16.4–21.7) 
Linear regression of log-concentration and 
trapezoidal rule 
[134] Adults, cystic fibrosis (20) 
25.4  
sd (±9.7) 
53.2  
sd (±8.2) 
Two 
compartment 
25.2 
(95% CI: 22.7–27.7) 
10.3* 
(95% CI: 8.7–12.0) 
Non-parametric approach. Ceftolazone-
tazobactam study. *central compartment only 
published 
[135] 
Healthy adults, 
japanese/chinese/white (29) 
34  
sd (± 8.3) 
63.0  
sd (± 7.8) 
Non-
compartmental 
23.6  
(95% CI: 21.9–25.3) 
28.4 
(95% CI: 26.7–30.2) 
 
Log-linear transformation, trapezoidal methods. 
Ceftolazone-tazobactam study. 
[118] 
Adults, healthy volunteers 
(11) 
29  
sd (±8.9) 
69.8  
sd (±15.7) 
Non-
compartmental  
11.6 
(95% CI: 10.5–12.8) 
11.6 
(95% CI: 10.5–12.8) 
Least squares regression analysis of log-linear 
plots and trapezoidal rule 
[119] 
Adults, healthy volunteers 
(12) 
25 range (23-30) 78.4  
range (60.4-96.3 
Non-
compartmental 
11.1 
(95% CI: 10.4–11.8) 
11.9 
(95% CI: 10.7–13.1) 
Non-linear iterative least-squares method 
[122] 
Adults, healthy volunteers 
(12) 
28  
sd (±8) 
70  
sd (±17) 
Non-
compartmental  
9.2 
(95% CI: 8.3–10.1) 
9.1 
(95% CI: 8.9–9.3) 
Least squares regression analysis of log-linear 
plots and trapezoidal rule 
[125] 
Adults, healthy volunteers, 
high dose tazobactam (10) 
30.7  
sd (±7.6) 
73.7  
sd (±15.5) 
Non-
compartmental  
8.0 
(95% CI: 6.7–9.3) 
63 
(95% CI: 39.3–86.7) 
Least squares regression analysis of log-linear 
plots and trapezoidal rule 
[127] Children, critically ill (47) 
2.8  
range (0.17-15) 
14  
range (3.4-45) 
Two 
compartment 
10.0 
(95% CI: 9.0–11.1) 
17.2 
(95% CI: 11.9–23.3) 
Non-linear least squares method 
[128] Children, critically ill (12) 
5  
IQR (1.75, 6.5) 
17.8 
 IQR (11.4,20) 
One 
compartment  
9.6 
(95% CI: 8.3–10.8) 
21.8 
(95% CI: 17.5–26.0) 
Non-linear least squares method 
[130] 
Children with suspected 
infection (11) 
6-12 Not reported Non-
compartmental  
4.9 
(95% CI: 0.5–9.3) 
19.6 
(95% CI: 14.9–24.3) 
Least squares regression analysis of log-linear 
plots and trapezoidal rule 
[130] 
Children with suspected 
infection (12) 
2-5 Not reported Non-
compartmental  
6.7 
(95% CI: 5.1–8.2) 
19.6 
(95% CI: 15.2–24.0) 
Least squares regression analysis of log-linear 
plots and trapezoidal rule 
[130] 
Children with suspected 
infection (12) 
0.5-2 Not reported Non-
compartmental  
4.9 
(95% CI: 3.7–6.1) 
21 
(95% CI: 16.6–25.4) 
Least squares regression analysis of log-linear 
plots and trapezoidal rule 
 This article is protected by copyright. All rights reserved. 
[130] 
Children with suspected 
infection (12) 
0.2-0.4  Non-
compartmental  
3.9 
(95% CI: 3.3–4.6) 
23.1 
(95% CI: 18.7–27.5) 
Least squares regression analysis of log-linear 
plots and trapezoidal rule 
[131] 
Infants and neonates treated 
for infection (71) 
PMA 37.5 weeks  
sd (±5) 
2.76  
sd (±1) 
Two 
compartment 
4.7 
(95% CI: 4.3–5.0) 
30.3 
(95% CI: 22.3–38.2) 
Non-linear mixed-effects 
[133] 
Infantes and neonates treated 
for infection (32) 
PMA 32 weeks 
range (25–48) 
1.4  
range (0.4–4.0) 
One 
compartment  
2.1 
(95% CI: 1.7–2.5) 
39.9 
(95% CI: 36.4–44.8) 
Non-linear mixed-effects. Dried blood spot 
samples 
Mean or median values presented. With associated range, interquartile range (IQR) or standard deviation (sd). 95% confidence intervals have been calculated, where standard deviation or standard error data was 
available, assuming a student’s t-distribution. GA is gestational age, PMA is post-menstrual age 
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Ref Population (n) 
Age (years unless 
other specified) 
Weight (kg) 
Structural 
model 
Clearance  
(L/h/70kg) 
Volume at steady state 
(L/70kg)* 
Comments/modelling approach 
Meropenem 
[32] Adults, critically ill, (19) 
49  
sd (±15.9) 
95  
sd (±22) 
Two 
compartment 
12.3 
(95% CI: 10.0–14.6) 
8.6* 
(95% CI: 6.6–10.6) 
Non-parametric adaptive grid algorithm. *central 
volume only published 
[33] 
Adults, critically ill, requiring 
haemofiltration (15) 
59  
range (33-85) 
82.3  
range (45-128.5) 
Two 
compartment 
7.9 
range (1.8–23.9) 
29.3 
range (17.5–69.4) 
Non-linear mixed-effects methods 
[34] Adults, critically ill (55) 
63.4  
sd (± 15.1) 
78.4  
sd (±18.4) 
Three 
compartment 
(one for lung) 
9.4 
(95% CI: 7.6–10.0) 
25.5 
(95% CI: 17.0–57.8) 
Non-linear mixed-effects methods 
[35] Adults, critically ill (15) 
73  
IQR (52, 94) 
78  
IQR (65.5, 90.5) 
Two 
compartment  
4.1 
(95% CI: 2.7–7.2) 
14.1 
(95% CI: 12.7–19.4) 
Non-linear regression (WinNonlin) 
[36] Adults, critically ill (27) 
62  
sd (±12) 
76.2  
sd (±30.3) 
One 
compartment 
8.8 
(95% CI: 7.1–10.5) 
24.1 
(95% CI: 18.8–29.4) 
Non-linear mixed-effects methods 
[37] Adults, critically ill (10) 
67  
sd (±19) 
72  
sd (±15) 
Two 
compartment 
11.3 
(95% CI: 9.1–13.4) 
26.3 
(95% CI: 21.0–31.7) 
Extended least squares regression method, 
trapezoidal rule 
[38] Adults, critically ill (15) 
55.3  
sd (±14.3) 
83.6  
sd (±15.4) 
Not specified 
7.5 
(95% CI: 6.7–8.3) 
21.9 
(95% CI: 19.8–24.1) 
Kinetica program 
[39] 
Adults, critically ill with 
severe infection/septic shock 
(50) 
67.5 (±13.9) 62.2  
sd (±11.2) 
One 
compartment 
15.1 
(95% CI: 13.2–16.9) 
30.7 
(95% CI: 29.2–32.3) 
WinNonlin 
[40] 
Adults, critically ill, elderly 
(178) 
75 range (65-94) 77  
range (37-147) 
Two 
compartment 
4.9 
(95% CI: 4.7–5.1) 
25.2 
(95% CI: 19.5–31.2) 
Non-linear mixed-effects methods 
[41] 
Adults, critically ill, elderly 
(75) 
75.6  
sd (±8.9) 
64.4  
sd (±12.3) 
Two 
compartment 
9.6 
(95% CI: 7.9–11.2) 
34.8 
(95% CI: 24.2–45.8) 
Non-linear mixed-effects methods 
[42] 
Adults, critically ill, requiring 
haemofiltration (10) 
67  
range (20–75) 
76  
range (50–113) 
Non-
compartmental 
4.5 
IQR (3.4, 14.3) 
17.4 
IQR (14.1, 23.4) 
Log-linear least squares regression and linear 
trapezoidal rule 
[43] 
Adults, critically ill with 
sepsis/septic shock (9) 
57.2  
sd (±16.1) 
62.9  
sd (±11.6) 
One 
compartment 
8.5 
(95% CI: 4.2–12.8) 
26.4 
(95% CI: 18.7–34.0) 
Non-linear mixed-effects methods 
[44] Adults, critically ill, obese (9) 
55.4  
sd (± 10.1) 
152.3  
sd (± 31) 
Two 
compartment 
5.7 
(95% CI: 3.5–7.8) 
17.2 
(95% CI: 12.0–22.4) 
Non-linear least squares regression 
[45] 
Adults, critically ill with 
central nervous system 
infection (21) 
52  
range (46-80) 
76  
range (55-105) 
Three 
compartment 
14.2 
range (7.6–29.9) 
12.7* 
range (5.1–15.0) 
Non parametric adaptive grid algorithm. *central 
volume only published 
[46] 
Adults, critically ill with 
central nervous system 
infection (9) 
45.1  
sd (±17.6) 
70.3  
sd (±12.6) 
Three 
compartment 
(two csf) 
7.2 
(95% CI: 4.0–15.8) 
99.6* 
(95% CI: 43.1–162.8) 
Non-linear mixed-effects methods. *central 
volume only published. Unusually high volume. 
[47] 
Adults, critically ill with 
central nervous system 
infection (10) 
61.5  
IQR (54.3, 68.3) 
80 
IQR (70, 79.7) 
Two 
compartment 
(one csf) 
14.6 
(95% CI: 9.9–19.3) 
10.7* 
(95% CI: 8.2–13.1) 
Non-parametric adaptive-grid 
Unusually high volume. *central volume only 
published 
[48] 
Adults, critically ill with 
central nervous system 
infection (82) 
43.4  
sd (±13.1) 
65.2  
sd (±11.6) 
Three 
compartment 
(one csf) 
23.4 
(95% CI: 21.6–25.3) 
19.4 
(95% CI: 17.4–21.0) 
Non-linear mixed-effects methods 
[49] 
Adults, critically ill requiring 
haemofiltration (10) 
57  
IQR (49, 61) 
70  
IQR (66, 103) 
Non-
compartmental 
6.0 
IQR (5.2, 6.2) 
25.9 
IQR (22.4, 32.2) 
Linear trapezoidal rule and log-linear least 
squares regression  
[50] 
Adults, critically ill requiring 
haemofiltration (10) 
64.9  
sd (± 8.0) 
79.8  
sd (±18.5) 
Two 
compartment 
3.9 
(95% CI: 3.0–4.8) 
23.9 
(95% CI: 17.8–30.0) 
Non-linear regression 
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[51] 
Adults, requiring 
haemofiltration (10) 
54.3  
sd (±9.4) 
76.7  
sd (±15.0) 
Non-
compartmental 
4.7 
range (2.4–11.2) 
50.4 
range (26.8–213.2) 
WinNonLin 
[52]  
Adults, anuric and requiring 
haemofiltration (9) 
54.2  
sd (±19.7) 
69.4  
sd (±9.7) 
Two 
compartment 
3.1 
(95% CI: 2.3–3.9) 
18.2 
(95% CI: 13.3–23.0) 
Weighted least squares regression.  
[53] 
Adults, critically ill requiring 
haemofiltration (15) 
60  
sd (±8.3) 
71  
sd (±16.3) 
Four 
compartment 
5.4 
(95% CI: 1.0–9.9) 
24.0 
(95% CI: 9.2–38.8) 
Compartmental approach. Kinetica program.  
[54] 
Adults, critically ill requiring 
haemofiltration (24) 
68.5  
range (50-81) 
75  
range (68-126) 
One 
compartment 
3.5 
(95% CI: 2.8–4.2) 
30.8 
(95% CI: 24.9–36.7) 
 
Non-linear mixed-effects methods 
[55] 
Adults, critically ill burn 
patients (59) 
47.3  
range (19–86) 
65.9  
range (42–95) 
Two 
compartment 
15.6 
(95% CI: 14.2–19.0) 
28.8 
(95% CI: 22.8–37.9) 
Non-linear mixed-effects methods 
[56] 
Adults, critically ill burns 
patients (12) 
46  
sd (±16) 
82.9  
sd (±17.5) 
Two 
compartment 
14.3 
(95% CI: 12.3–16.3) 
40.7 
(95% CI: 31.1–50.3) 
Non-linear mixed-effects methods 
[57] 
Adults, critically ill with 
ventilator associated 
pneumonia (9) 
39.6  
sd (±15.8) 
54.2  
sd (± 11.6) 
One 
compartment  
10.3 
(95% CI: 7.3–13.3) 
20.7 
(95% CI: 17.0–24.3) 
Trapezoidal rule 
[58] 
Adults, critically ill with 
ventilator associated 
pneumonia (39) 
49.3  
sd (±19.4) 
83.1  
sd (±22.6) 
Three 
compartment 
(one lung) 
13.4 
(95% CI: 10.6–16.1) 
10.6* 
(95% CI: 7.0–14.2) 
Non-parametric adaptive-grid. *central 
compartment only 
[59] 
Adults, critically ill surgical 
patients (32) 
68.5  
IQR (62, 76) 
73.5  
IQR (69, 89) 
Not reported 
10.4  
(95% CI: 8.8–12.6) 
Not reported Non-linear mixed-effects methods 
[60] 
Adults, surgical patients with 
moderate or severe infection 
(11) 
63.1  
sd (±18.3) 
72  
range (47.6–95) 
Two 
compartment 
11.2 
(95% CI: 8.8–13.5) 
20.1 
(95% CI: 16.6–23.7) 
Extended or least squares method 
[61] 
Adults, intra-abdominal 
infection (12) 
29.5  
sd (±13.1) 
70.95  
sd (±7.7) 
Non-
compartmental 
18.7 
(95% CI: 16.0–21.4) 
26.3 
(95% CI: 22.0–30.6) 
LAGRAN program 
[33] 
Adults, haematological 
malignancy and infection (10) 
52  
range (35-75) 
72  
range (48-85) 
Two 
compartment 
12.8 
range (10.5–20.7) 
22.7 
range (15.0–37.0) 
Non-linear mixed-effects methods 
[62] 
Adults, haematological 
malignancy and  febrile 
neutropenia (57) 
36  
range (17-68) 
61.4  
range (45-95.8) 
One 
compartment 
10.7 
(95% CI: 8.3–13.0) 
16.6 
(95% CI: 12.6–20.6) 
Non-linear mixed-effects methods 
[63] 
Adults, haematological 
malignancy and  febrile 
neutropenia (12) 
61  
range (36–82) 
Not published 
Non-
compartmental 
8.94 
(95% CI: 6.2–11.6) 
16.2 
(95% CI: 13.7–18.7) 
Least square regression analysis, trapezoidal rule 
[64] 
Adults, hospitalised with 
infection (68) 
71.5  
sd (±13.5) 
52.1  
sd (±13.9) 
One 
compartment  
13.9 
(95% CI: 11.4–16.5) 
45.1 
(95% CI: 32.5–56.6) 
Non-linear mixed-effects methods 
[65] 
Adults, hospitalised with 
infection (42) 
62.2  
sd (±19.6) 
56  
sd (± 10.4) 
Two 
compartment 
10.7 
(95% CI: 5.0–16.4) 
21.1 
(95% CI: 17.9–24.6) 
Non-linear mixed-effects methods 
[66] 
Adults, obese, hospitalised 
with infection (10) 
49.1  
sd (±12.0) 
200.4  
sd (±67.9) 
Two 
compartmetns 
3.7 
(95% CI: 2.8–4.5) 
8.8 
(95% CI: 6.5–11.0) 
Nonlinear least-squares regression 
[67] 
Adults, obese, hospitalised 
with infection (375) 
64.7  
sd (±13.4) 
95.3  
sd (±18) 
One 
compartment  
7.0 
(95% CI: 6.5–7.5) 
20.6 
(95% CI: 20.5–20.7) 
ADAPT 5 program 
[68] 
Adults, healthy volunteers 
(12) 
29.4  
sd (±6) 
80.3  
sd (±7.2) 
Non-
compartmental/t
wo compartment 
14.4 
(95% CI: 13.3–15.5) 
18.6 
(95% CI: 15.9–21.3) 
Log trapezoid rule, iterative least squares method 
[69] 
Adults, healthy volunteers 
(12) 
32.6  
sd (± 8.9) 
59.7  
sd (±7.8) 
One 
compartment 
11.5 
(95% CI: 7.9–15.1) 
19.7 
(95% CI: 15.9–23.5) 
WinNonlin 
[70] Adults, healthy volunteers (9) 
36.6  
range (23–59) 
79.0  
range (67.9–89.7) 
Two 
compartment 
13.7 
(95% CI: 12.0–15.4) 
14.8 
(95% CI: 12.8–16.8) 
Least squares regression  
 This article is protected by copyright. All rights reserved. 
[71] 
Adults, healthy volunteers 
(18) 
38  
sd (±10) 
74.4  
sd (±9.1) 
Two 
compartment 
13.1 
(95% CI: 11.6–14.7) 
9.7* 
(95% CI: 8.3–11.1) 
Nonparametric adaptive grid program. *Central 
volume only reported 
[72] 
Adults, healthy volunteers 
(25) 
39.0  
sd (±10.6) 
80.3  
sd (9.4) 
Non-
compartmental 
10.0 
(95% CI: 9.2–10.8) 
14.2 
(95% CI: 13.3–15.1) 
Linear trapezoidal method 
[73] 
Adults, healthy elderly (8) 
Included as no other elderly 
studies 
73  
sd (±4.6) 
68.9  
sd (±8.3) 
Non-
compartmental 
8.3 
(95% CI: 6.9–9.7) 
13.2 
(95% CI: 12.0–14.4) 
Least-squares regression, log-trapezoidal rule 
[74] 
Children with malignancy and 
severe infection (14) 
7.1  
sd (±2.4) 
22.7  
sd (±9.7) 
Two 
compartment 
15.2 
(95% CI: 12.8–18.4) 
12.5 
(95% CI: 9.6–17.1) 
Non-linear mixed-effects methods 
[75] 
Children with infection 
following stem cell transplant 
(21) 
9.6  
sd (±5.4) 
36.1  
sd (±20.5) 
Non-
compartmental 
8.2 
IQR (5.0, 15.6) 
Not calculated 
Clearance at steady state calculated from infusion 
rate/concentration at steady state 
[76] Children with infection (99) 
4.3  
sd (±3.8) 
16.8  
sd (± 11.6) 
Two 
compartment 
12.3 
(95% CI: 11.5–13.7) 
12.2 
(95% CI: 9.7–14.4) 
Non-linear mixed-effects methods 
[77] 
Children (40) 
*pooled data from Japanese 
articles 
6.6  
sd (±4.4) 
23.2  
sd (±13.5) 
Two 
compartment 
13.5 
(95% CI: 8.9–18.0) 
35 
(95% CI: 19.3–44.5) 
Non-linear mixed-effects methods. Pooled 
participant group. 
[78] 
Children, hospitalised with 
infection (50) 
3.1  
sd (±3.2) 
14.8  
sd (±8.1) 
Two 
compartment 
10.4 
(95% CI: 9.7–11.2) 
23.8 
(95% CI: 30.1–39.2) 
Non-linear mixed-effects methods 
[79] 
Children with cystic fibrosis 
and lung infection (30) 
12.7  
sd (±2.9) 
40.9  
sd (±12.2) 
Two 
compartment 
24.1 
(95% CI: 18.9–29.3) 
21.0* 
(95% CI: 16.7–25.3) 
Non-parametric adaptive grid. *central volume 
only published 
[80] 
Children, requiring 
haemofiltration (7) *included 
as only study in children 
14.3  
sd (±5.8) 
48.6  
sd (±17.4) Not specified 
3.7 
(95% CI: 2.1–7.7) 
24.5 
(95% CI: 19.0–30.0) 
Bayesian estimation using MWPharm 
[81] 
Infants and children, 
hospitalised with infection 
(63) 
4  
sd (±3.5) 
16.5  
sd (±11) 
Non-
compartmental 
16.2 
(95% CI: 14.9–17.4) 
30.1 
(95% CI: 28.2–32.1) 
Linear trapezoidal rule and log-linear least 
squares regression 
[82] Neonates (188) 
PMA 33 weeks 
range (24-51) 
1.1  
range (0.3-4.8) 
One 
compartment 
2.9 
(95% CI: 2.8–3.1) 
32.2 
(95% CI: 30.3–34.1) 
Non-linear mixed-effects methods 
[83] Neonates (22) 
PNA 
10 days (±15) GA 
34 (±5) 
2.4  
sd (±1) 
One 
compartment 
1.0 
range not published 
28 
range not published 
Non-linear mixed-effects methods 
[84] Neonates (9) 
GA 26.9  
sd (±1.4) wk PNA 
15.6  
sd (±8.6) days 
0.9  
sd (±0.2) Non-
compartmental 
1.4 
(95% CI: 0.9–1.9) 
21.0 
(95% CI: 13.3–28.7) 
WinNonlin 
Mean or median values presented. With associated range, interquartile range (IQR) or standard deviation (sd). 95% confidence intervals have been calculated, where standard deviation or standard error data was 
available, assuming a student’s t-distribution. GA is gestational age, PMA is post-menstrual age 
 
 
